Heterologous Prime-Boost Vaccination with the LACK Antigen Protects against Murine Visceral Leishmaniasis
Open Access
- 1 August 2005
- journal article
- research article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 73 (8) , 5286-5289
Abstract
This study reports the efficacy of a heterologous prime-boost vaccination using DNA and vaccinia viruses (Western Reserve [WR] virus and modified [attenuated] vaccinia virus Ankara [MVA]) expressing the LACK antigen (Leishmaniahomologue of receptors for activated C kinase) and an intradermal murine infection model employingLeishmania infantum. At 1 month postinfection, vaccinated mice showed high levels of protection in the draining lymph node (240-fold reduction in parasite burden) coupled with significant levels of gamma interferon (20 to 200 ng/ml) and tumor necrosis factor alpha/lymphotoxin (8 to 134 pg/ml). Significant but lower levels of protection (6- to 30-fold) were observed in the spleen and liver. Comparable levels of protection were found for mice boosted with either LACK-WR or LACK-MVA, supporting the use of an attenuated vaccinia virus-based vaccine against human visceral leishmaniasis.Keywords
This publication has 47 references indexed in Scilit:
- Microarray Analysis Reveals Characteristic Changes of Host Cell Gene Expression in Response to Attenuated Modified Vaccinia Virus Ankara Infection of Human HeLa CellsJournal of Virology, 2004
- A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c miceVaccine, 2004
- Protection against Cutaneous Leishmaniasis in Outbred Vervet Monkeys, Using a Recombinant Histone H1 AntigenThe Journal of Infectious Diseases, 2003
- Intradermal Infection Model for Pathogenesis and Vaccine Studies of Murine Visceral LeishmaniasisInfection and Immunity, 2003
- Enhanced CD8+ T cell immune response against a V3 loop multi-epitope polypeptide (TAB13) of HIV-1 Env after priming with purified fusion protein and booster with modified vaccinia virus Ankara (MVA-TAB) recombinant: a comparison of humoral and cellular immune responses with the vaccinia virus Western Reserve (WR) vectorVaccine, 2001
- Leishmania donovanip36(LACK) DNA Vaccine Is Highly Immunogenic but Not Protective against Experimental Visceral LeishmaniasisInfection and Immunity, 2001
- Protection against Cutaneous Leishmaniasis Induced by Recombinant Antigens in Murine and Nonhuman Primate Models of the Human DiseaseInfection and Immunity, 2001
- Tissue Cytokine Responses in Canine Visceral LeishmaniasisThe Journal of Infectious Diseases, 2001
- Visceral Leishmaniasis in Mice Devoid of Tumor Necrosis Factor and Response to TreatmentInfection and Immunity, 2000
- Killing of Leishmania donovani Amastigotes by Poly ICLC in HamstersJournal of Interferon & Cytokine Research, 1996